

Mouse Anti Human CD15 Monoclonal Antibody, FITC

DMABT-45612MH Mouse(CD15)

Lot. No. (See product label)

PRODUCT INFORMATION

Product Overview	Mouse Anti Human CD15,FITC
Immunogen	Human granulocytes
Host	Mouse
Isotype	IgM
Species	Human
Clone	NFN-269
Conjugation	FITC
Applications	FCM,
Dilution	FCM: Neat - 1/10

PACKAGING

Format	Purified IgM conjugated to Fluorescein Isothiocyanate Isomer 1 (FITC) - liquid
Protein Concentration	Ig concentration 0.1 mg/ml
Buffer	Phosphate buffered saline
Storage	Store at +4 °C. DO NOT FREEZE. This product should be stored undiluted. This product is photosensitive and should be protected from light. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
Preservative	0.09% Sodium Azide 1% Bovine Serum Albumin
Shelf Life	18 months from date of despatch.

BACKGROUND

Introduction	<p>CD15 (3-fucosyl-N-acetyl-lactosamine) is a cluster of differentiation antigen - an immunologically significant molecule. CD15 is a carbohydrate adhesion molecule (not a protein) that can be expressed on glycoproteins, glycolipids and proteoglycans. CD15 is expressed on Reed-Sternberg cells of Hodgkin's disease and by various other cell types including myeloid cells and epithelial cells. Antibodies to CD15 recognize a pentasaccharide sequence occurring in lacto-N-fucopentaose III ceramide (also referred to as X hapten of Lex) found in higher glycolipids and glycoproteins. A review by Arber et al. has reported that antibodies to CD15 demonstrate positive staining in 87% of Hodgkin's disease including nodular sclerosing, mixed cellularity, and lymphocyte depletion, whereas the lymphocyte predominant variant exhibits a lower rate of positivity (37%). Among non-Hodgkin's lymphoma, 13% express CD15 including 4.1% B-cell, 21% T-cell, and 17% null-cell. CD15 expression has also been demonstrated in acute myeloid leukemia (65%) and chronic myelogenous leukemia (96% chronic phase and 54% blast phase). A relatively low level of CD15 expression has been reported in acute lymphoblastic leukemia (5.7% overall) with positivity observed in 7.7% common or precursor B-cell, 0% B-cell, 7.7% T-cell and 17.3% nullcell. Carcinomas derived from various organs have also been shown to be CD15 positive (56%) including adenocarcinomas, squamous cell carcinomas and undifferentiated large and small cell carcinomas.</p>
---------------------	--

Keywords

fucosyltransferase; Alphafucosyltransferase; Alpha 13 fucosyltransferase FucT; Alpha-1 ELAM ligand fucosyltransferase; ELAM-1 ligand fucosyltransferase; ELAM1 ligand fucosyltransferase; ELFT; FCT3A; Fuc-TIV; Fucosyltransferase 4 alpha 1 3 fucosyltransferase myeloid specific; Fucosyltransferase 4; Fucosyltransferase IV; FucT IV; FucT-IV; FUCTIV; FUT4; FUT4_HUMAN; Galactoside 3 L fucosyltransferase; Galactoside 3-L-fucosyltransferase; LeX; SSEA 1; SSEA1; Stage specific embryonic antigen 1